Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and
ixabepilone when administered on day 1 of a 3 week treatment course.